Welcome to Multibagg AI
Log in to access personalized features
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY24
Discovery themes featuring this stockDiscovery themes featuring this stock
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Lupin Ltd (LUPIN) is currently trading at 2,245.30 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Lupin is a global, innovation-led pharmaceutical company that develops and markets branded and generic formulations, biosimilars, injectables, inhalation products and APIs across 100+ countries, with particular strength in cardiovascular, diabetology, respiratory and anti-TB. The company combines a large India commercial footprint with a growing regulated-market presence in the United States and other developed markets. Q3 FY26 was a company record: consolidated sales of INR 71,005 million (↑26% YoY), EBITDA of INR 22,095 million (↑62% YoY) with a 31.1% margin, and net income of INR 11,756 million (↑38% YoY); Lupin highlighted broad-based regional growth led by a USD 350 million quarter in the US, driven by Tolvaptan, Mirabegron and new product momentum. Lupin is pivoting R&D and commercial strategy toward complex generics, injectables and biosimilars: the company announced US FDA approval for pegfilgrastim (Armlupeg™), has a rich pipeline of inhalation, injectables and biosimilars targeting multiple launches through FY28–FY31, and plans 10–15 ANDA filings in FY26 while targeting 100+ new product launches across platforms by FY31. India remains a core growth engine with the Rx business growing 10.9% in Q3 FY26 and chronic therapies now ~67% of the portfolio; Lupin is building a semaglutide-focused division, expects to be a day-one participant in obesity/GLP-1 launches, and projects sustained outperformance of the domestic market through product launches and salesforce expansion. Lupin is strengthening its ESG credentials while scaling complex product capability: the company achieved a 91/100 S&P Global ESG rating, CDP double A, SBTi approval for GHG targets and is advancing water recycling and zero-waste initiatives, underlining a simultaneous focus on sustainability, regulatory compliance improvements and quality remediation across manufacturing sites.
Over the past 52 weeks, Lupin Ltd has traded between a low of ₹1,774.00 and a high of ₹2,261.95. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Lupin Ltd has a market capitalization of approximately 1,01,749.25. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Lupin Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 20.43 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,01,749.25 Cr, Lupin Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Lupin Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Lupin Ltd is 20.43. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The most significant announcement is the 'Biopharma Shakti' scheme, with a ₹10,000 crore outlay to make India a global hub for biopharma manufacturing, directly supporting Lupin's focus on biosimilars and complex drugs.
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1348.00 | 1,08,978 Cr | 22.90 | 3.31 | 1.19 | 16.53 | 21.05 | 11.32 | |
1283.00 | 1,06,904 Cr | 19.23 | 2.97 | 0.62 | 16.03 | 18.66 | 10.16 | |
2223.80 | 1,01,749 Cr | 20.43 | 5.18 | 0.54 | 22.03 | 21.92 | 13.94 | |
910.05 | 91,572 Cr | 17.91 | 3.62 | 1.21 | 19.44 | 19.08 | 10.52 | |
2072.00 | 85,665 Cr | 46.03 | 5.60 | 0.00 | 11.45 | 12.34 | 6.26 | |
1171.20 | 67,358 Cr | 19.26 | 1.92 | 0.00 | 9.77 | 12.69 | 6.63 | |
5463.60 | 65,331 Cr | 27.20 | 4.90 | 0.82 | 17.69 | 18.13 | 11.95 |
Earnings Call Transcript
Transcript of Lupin's Q3 FY26 earnings call: revenue INR 7,168 Cr (+24% YoY), EBITDA margin 31.1%, US sales USD 350m (+46% YoY), approval of pegfilgrastim biosimilar, broad-based regional growth and strong R&D spend.
Concall Transcript
Lupin reports Q3 FY26 revenue of INR 7,168 crore (+24% YoY), EBITDA margin 31.1%, US sales $350m (+46% YoY); US FDA approval for Pegfilgrastim biosimilar and multiple launches/partnerships to drive growth.
License and Supply Agreement
Lupin signed a license and supply agreement with Spektus to commercialize the novel antidepressant DeslaFlex™ in Canada, expanding its CNS portfolio and Canadian commercial footprint.
Newspaper Publication
Lupin published a newspaper advertisement under Reg. 47/30 enclosing the extract of its unaudited financial results for the quarter and nine months ended December 31, 2025, filed with NSE and BSE on Feb 14, 2026.
Postal Ballot Result
On Feb 13, 2026, Lupin shareholders passed a special resolution approving appointment of Mr. Anand Kripalu (DIN:00118324) as Independent Director; promoters cast 214,212,684 votes (100% of promoter votes) in favour.
Postal Ballot Outcome
Lupin Limited announced that shareholders approved, via postal ballot on Feb 13, 2026, the special resolution to appoint Mr. Anand Kripalu (DIN: 00118324) as an Independent Director; promoters (214,212,684 shares) voted 100% in favour; Postal Ballot notice dated Jan 06, 2026 and record date Jan 09, 2026; scrutinizer report enclosed.
Bearish
5
Neutral
6
Bullish
3
Bearish
5
Neutral
6
Bullish
35
Bearish
0
Neutral
0
Bullish
32
Lupin is a global, innovation-led pharmaceutical company that develops and markets branded and generic formulations, biosimilars, injectables, inhalation products and APIs across 100+ countries, with particular strength in cardiovascular, diabetology, respiratory and anti-TB. The company combines a large India commercial footprint with a growing regulated-market presence in the United States and other developed markets.
Q3 FY26 was a company record: consolidated sales of INR 71,005 million (↑26% YoY), EBITDA of INR 22,095 million (↑62% YoY) with a 31.1% margin, and net income of INR 11,756 million (↑38% YoY); Lupin highlighted broad-based regional growth led by a USD 350 million quarter in the US, driven by Tolvaptan, Mirabegron and new product momentum.
Lupin is pivoting R&D and commercial strategy toward complex generics, injectables and biosimilars: the company announced US FDA approval for pegfilgrastim (Armlupeg™), has a rich pipeline of inhalation, injectables and biosimilars targeting multiple launches through FY28–FY31, and plans 10–15 ANDA filings in FY26 while targeting 100+ new product launches across platforms by FY31.
India remains a core growth engine with the Rx business growing 10.9% in Q3 FY26 and chronic therapies now ~67% of the portfolio; Lupin is building a semaglutide-focused division, expects to be a day-one participant in obesity/GLP-1 launches, and projects sustained outperformance of the domestic market through product launches and salesforce expansion.
Lupin is strengthening its ESG credentials while scaling complex product capability: the company achieved a 91/100 S&P Global ESG rating, CDP double A, SBTi approval for GHG targets and is advancing water recycling and zero-waste initiatives, underlining a simultaneous focus on sustainability, regulatory compliance improvements and quality remediation across manufacturing sites.
Pharmaceuticals
Pharmaceuticals - Indian - Bulk Drugs & Formln Lrg
1,01,749 Cr
Moderate Risk
20.4
26.5
—
5.2
2,261.95
1,774.00
Sales CAGR
Profit CAGR
ROE
ROCE
